Treatment of AIDS and HIV-Related conditions -1996

Journal of the American Board of Family Practice

Volumn 9, Issue 2, 1996, Pages 125-148

  Goldscbmidt, Ronald H ^a   Dong, Betty J ^a  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AIDS RELATED COMPLEX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; REVIEW; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERANCE; OPPORTUNISTIC INFECTION; SIDE EFFECT;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS-RELATED OPPORTUNISTIC INFECTIONS; HIV INFECTIONS; HUMANS;

ANTIVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; RITONAVIR; SAQUINAVIR; STAVUDINE; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

EID: 0030095840     PISSN: 08938652     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (88)

1. Goldschmidt RH, Dong BJ. Treatment of AIDS and HTV-related conditions - 1995. J Am Board Fam Practl995;8:139-62.
2. Volberding PA, Lagakos SW, Grimes JM, Stein DS, RooneyJ, Meng T-C, et al. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. N Engl J Med 1995;333:401-7.
3. Lundgren JD, Phillips AN, Pedersen C, Clumeck N, GatellJM, Johnson AM, et al. Comparison of longterm prognosis of patients with AIDS treated and not treated with zidovudine. JAMA 1994;2 71:1088-92.
4. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Concorde Coordinating Committee. Lancet 1994;343:871-81.
5. Volberding PA, Lagakos SW, Grimes JM, Stein DS, Balfour HH Jr, Reichman RC, et al. The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. JAMA 1994;272: 437-42.
6. loannidis JP, Cappelleri JC, Lau J, Skolnik PR, Melville B, Chalmers TC, et al. Early or deferred zidovudine therapy in HIV-infected patients without an AIDSdefining illness. Ann Intern Med 1995;122:856-66.
7. Moore RD, Chaisson RE, Hidalgo J. The efficacy of zidovudine is time limited. JAMA 1994;272:1001.
8. Spooner KM, Lane HC, Masur H. Antiretroviral therapy: reference guide to major clinical trials in patients infected with human immunodeficiency virus. Clin Infect Dis 1995;20:1145-51.
9. Lipsky JJ. Zalcitabine and didanosine. Lancet 1993;341:30-2.
10. 3. A doubleblind, randomized, controlled trial. Ann Intern Med 1995;123:561-71.
11. Eron JJ, Benoit SL, JemsekJ, MacArthur RD, Santana J, QuinnJB, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J. Med 1995;333:1662-9.
12. Lipsky JJ. The glimmer of HIV proteinase inhibitors. Lancet 1995;345:936-7.
13. Hammer S, Katzenstein D, Hughes M, Gundacker H, Hirsch M, and Merigan T for the ACTG 175 Study Team NIAID Sponsored AIDS Clinical Trials Group. Nucleoside monotherapy (MT) vs combination therapy (CT) in HIV infected adults: a randomized double-blind, placebo-controlled trial in persons with CD4 cell counts 200-500/mm3. In: Program and abstracts of die 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 17-20, 1995. Washington, DC: American Society for Microbiology, 1995:8. Abstract.
14. Choo V. Combination superior to zidovudine in Delta trial. Lancet 1995;346:895.
15. Sande MA, Carpenter CG, Cobbs CG, Holmes KK, Sanford JP. Antiretroviral therapy for adult HIV-infected patients. Recommendations from a state-ofthe-art conference. JAMA 1993;270:2583-9.
16. Goldschmidt RH, Dong BJ, LeggJJ. Antiretroviral strategies revisited. J Am Board Fam Pract 1995;8: 62-9.
17. Centers for Disease Control and Prevention. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary. MMWR 1995; 44(RR-8):l-34.
18. Centers for Disease Control. Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with human immunodeficiency virus. MMWR 1992 ;41 (RR-4): 1-11.
19. Masur H. Prevention and treatment of Pneumocystis pneumonia. N Engl J Med 1992;328:1853-60.
20. Heald A, Flepp M, Chave JP, Malinverni R, Riittimann S, Gabriel V, et al. Treatment for cerebral toxoplasmosis protects against Pneumocystis carinii pneumonia in patients with AIDS. The Swiss HIV Cohort Study. Ann Intern Med 1991;! 15:760-3.
21. Podzamczer D, Salazar A, JimenezJ, Consiglio E, Santin M, Casanova A, et al. Intermittent trimethoprim-sulfamethoxazole compared with dapsonepyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV. Ann Intern Med 1995; 122:755-61.
22. Carr A, Tindall B, Brew BJ, Marriott DJ, Harkness JL, Penny R, et al. Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS. Ann Intern Med 1992; 117:106-11.
23. Masur H. Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus. Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium Complex. N Engl J Med 1993;329:898-904.
24. Centers for Disease Control and Prevention. Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex for adults and adolescents infected with human immunodeficiency virus. US. Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium Avium Complex. MMWR 1993;42(RR-9):14-20.
25. Nightingale SD, Cameron DW, Gordin FM, Sullam PM, Cohn DL, Chaisson RE, et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med 1993;329: 828-33.
26. Goldschmidt RH, Dong BJ. Rifabutin prophylaxis against Mycobacterium avium complex disease. J Am Board Fam Pract 1994;7:58-61.
27. Goldschmidt RH, Hearst N, Chambers DB. Rifabutin prophylaxis against Mycobacterium avium complex infection. N Engl J Med 1994;330:436-7.
28. Consensus statement on the use of corticosteroids as adjunctive therapy for Pneumocystis pneumonia in die acquired immunodeficiency syndrome. The National Institutes of Health-University of California Expert Panel for Corticosteroids as Adjunctive Therapy for Pneumocystis Pneumonia. N Engl J Med 1990; 323:1500-4.
29. BlackJR, FeinbergJ, Murphy RL, Pass RJ, Finkelstein D, Akil B, et al. Clindamycin and primaquine therapy for mild-to-moderate episodes of Pneumocystis carinii pneumonia in patients with AIDS: AIDS Clinical Trials Group 044. Clin Infect Dis 1994; 18:905-13.
30. Bozzette SA, Finkelstein DM, Spector SA, Frame P, Powderly WG, He W, et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995;332:693-9.
31. Hughes W, Leoung G, Kramer F, Bozzette SA, Safrin S, Frame P, et al. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients widi AIDS. N EnglJ Med 1993;328:1521-7.
32. Sattler FR, Frame P, Davis R, Nichols L, Shelton B, Akil B, et al. Trimetrexate with leucovorin versus trimethoprim-sulfamethoxazole for moderate to severe episodes of Pneumocystis carinii pneumonia in patients with AIDS: a prospective, controlled multicenter investigation of the AIDS Clinical Trials Group protocol 029/031. J Infect Dis 1994;170:165-72.
33. Jung AC, Paauw DS. Management of adverse reactions to trimethoprim-sulfamethoxazole in human immunodeficiency virus-infected patients. Arch Intern Med 1994; 154:2402-6.
34. Gluckstein D, Ruskin J. Rapid oral desensitization to trimethoprim-sulfamethoxazole (TMP-SMZ): use in prophylaxis for Pneumocystis carinii pneumonia in patients with AIDS who were previously intolerant to TMP-SMZ. Clin Infect Dis 1995;20:849-53.
35. Hirschtick RE, Glassroth J, Jordan MC, Wilcosky TC, Wallace JM, Kvale PA, et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus. N EnglJ Med 1995;333:845-51.
36. Safrin S, Crumpacker C, Chaos P, Davis R, Hafner R, Rush J, et al. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. N EnglJ Med 1991;325:551-5.
37. Balfour HHJr, Benson C, BraunJ, Cassens B, Erice A, Friedrnan-Kien A, et al. Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections. J Acquir Immune Defic Syndr 1994;7:2 54-60.
38. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. Studies of Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. N EnglJMed 1992;326:213-20.
39. Dieterich DT, Poles MA, Lew EA, Mendez PE, Murphy R, Addessi A, et al. Concurrent use of ganciclovir and foscarnet to treat cytomegalovirus infection in AIDS patients. J Infect Dis 1993;167:1184-8.
40. Intravenous versus oral ganciclovir: European/Australian comparative study of efficacy and safety in the prevention of cytomegalovirus retinitis recurrence in patients with AIDS. The Oral Ganciclovir European and Australian Cooperative Study Group. AIDS 1995;9:471-7.
41. Drew WL, Ives D, Lalezari JP, Crumpacker C, Follansbee SE, Spector SA, et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med 1995;333:615-20.
42. Holland GN, Tufail A. New therapies for cytomegalovirus retinitis. N Engl J Med 1995;333:658-9.
43. Ernest JT. Intraocular device for cytomegalovirus infection. Lancet 1995;346:983-4.
44. Kim YS, Hollander H. Polyradiculopathy due to cytomegalovirus: report of two cases in which improvement occurred after prolonged therapy and review of the literature. Clin Infect Dis 1993;17:32-7.
45. Berger TG, Obuch ML, Goldschmidt RH. Dermatologie manifestations of HIV infection. Am Earn Physician 1990;41:1729-42.
46. Cohen PR, Grossman ME. Recognizing skin lesions of systemic fungal infections in patients with AIDS. Am Earn Physician 1994;49:1627-34.
47. Adal KA, Cockerell CJ, Pétri WA Jr. Cat scratch disease, bacillary angiomatosis, and other infections due to Rochalimaea. N Engl J Med 1994;330:1509-15.
48. Koehler JE, Tappero JW. Bacillary angiomatosis and bacillary peliosis in patients infected with human immunodeficiency virus. Clin Infect Dis 1993; 17:612-24.
49. Macallan DC, Noble C, Baldwin C, Jebb SA, Prentice AM, Coward WA, et al. Energy expenditure and wasting in human immunodeficiency virus infection. NEnglJMed 1995;333:83-8.
50. Von Roenn JH, Armstrong D, Kotler DP, Cohn DL, Klimas NG, Tchekmedyian NS, et al. Megestrol acetate in patients with AIDS-related cachexia. Ann Intern Med 1994;121:393-9.
51. Oster MH, Enders SR, Samuels SJ, Cone LA, Hooton TM, Browder HP, et al. Megestrol acetate in patients with AIDS and cachexia. Ann Intern Med 1994; 121:400-8.
52. Grunfeld C, Feingold KR. Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. N EnglJMed 1992;327:329-37.
53. Mulligan K, Grunfeld C, Hellerstein MK, Neese RA, Schambelan M. Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab 1993;77:956-62.
54. DuPont HL, Marshall GD. HIV-associated diarrhoea and wasting. Lancet 1995;346:352-6.
55. White AC Jr, Chappell CL, Hayat CS, Kimball KT, Flanigan TP, Goodgame RW. Paromomycin for cryptosporidiosis in AIDS: a prospective, doubleblind trial.J Infect Dis 1994;170:419-24.
56. Simon DM, Cello JP, Valenzuela J, Levy R, Dickerson G, Goodgame R, et al. Multicenter trial of octreotide in patients with refractory acquired immunodeficiency syndrome-associated diarrhea. Gastroenterology 1995;108:1753-60.
57. Blanshard C, Benhamou Y, Dohin E, Lernestedt JO, Gazzard BG, Katlama C. Treatment of AIDS-associated gastrointestinal cytomegalovirus infection with foscarnet and ganciclovir: a randomized comparison. J Infect Dis 1995;172:622-8.
58. Simpson DM, Tagliati M. Neurologic manifestations of HIV infection. Ann Intern Med 1994;121:769-8S.
59. Newton HB. Common neurologic complications of HIV-1 infection and AIDS. Am Fam Physician 1995; 51:387-98.
60. Luft BJ, Hafher R, Korzun AH, Leport C, Antoniskis D, Bosler EM, et al. Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. NEnglJ Med 1993;329:995-1000.
61. Kovacs JA. Toxoplasmosis in AIDS: keeping the lid on. Ann Intern Med 1995; 123:230-1.
62. Powderly WG. Cryptococcal meningitis and AIDS. Clin Infect Dis 1993;17:837-42.
63. Saag MS, Powderly WG, Cloud GA, Robinson P, Grieco MH, Sharkey PK, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N EnglJMed 1992;326:83-9.
64. Powderly WG, Saag MS, Cloud GA, Robinson P, Meyer RD, JacobsonJM, et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 1992; 326:793-8.
65. Haubrich RH, Haghighat D, Bozzette SA, Tilles J, McCutchan JA, and the California Collaborative Treatment Group. High-dose fluconazole for treatment of cryptococcal disease in patients with human immunodeficiency virus infection. J Infect Dis 1994; 170:238-42.
66. Hook EW 3d, Marra CM. Acquired syphilis in adults. NEnglJ Med 1992;326:1060-9.
67. Gordon SM, Eaton ME, George R, Larsen S, Lukehart SA, Kuypers J, et al. The response of symptomatic neurosyphilis to high-dose intravenous penicillin G in patients with human immunodeficiency virus infection. N EnglJMed 1994;331:1469-73.
68. Malone JL, Wallace MR, Hendrick BB, LaRocco A Jr, Tonon E, Brodine SK, et al. Syphilis and neurosyphilis in a human immunodeficiency virus type-1 seropositive population: evidence for frequent sérologie relapse after therapy. Am J Med 1995;99:55-63.
69. Centers for Disease Control and Prevention. 1993 sexually transmitted diseases treatment guidelines. MMWR 1993;42(RR-14):1-102.
70. Centers for Disease Control. The use of preventive therapy for tuberculosis infection in the United States. Recommendations of the Advisory Committee for Elimination of Tuberculosis. MMWR 1990;39 (RR-8):9-12.
71. Centers for Disease Control. Initial therapy for tuberculosis in the era of multidrug resistance. Recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR 1993;42 (RR-7):l-8.
72. Iseman MD. Treatment of multidrug-resistant tuberculosis. N EnglJMed 1993;329:784-91.
73. Horsburgh CR Jr. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. NEnglJMedl991;324:1332-8.
74. Wolinsky E. Mycobacterial diseases other than tuberculosis. Clin Infect Dis 1992;15:1-10.
75. Diamond RD. The growing problem of mycoses in patients infected with the human immunodeficiency virus. Rev Infect Dis 1991; 13:480-6.
76. Fungal infection in HFV-infected persons. American Thoracic Society. Am J Respir Grit Care Med 1995;152:816-22.
77. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N EnglJ Med 1994;330:263-72.
78. Powderly WG, Finkelstein DM, FeinbergJ, Frame P, He W, van der Horst C, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N EnglJ Med 1995;332:700-5.
79. Wheat J, Hafner R, Korzun AH, Limjoco MT, Spencer P, Larsen RA, et al. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. Am J Med 1995; 98:336-42.
80. Wheat J, Hamer R, Wulfsohn M, Spencer P, Squires K, Powderly W, et al. Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome.
81. Lee BL, Safrin S. Interactions and toxicities of drugs used in patients with AIDS. Clin Infect Dis 1992; 14:773-9.
82. Coopman SA, Johnson RA, Platt R, Stern RS. Cutaneous disease and drug reactions in HIV infection. N EnglJMed 1993;328:1670-4.
83. White MY, Haddad ZH, Brunner E, Sainz C. Desensitization to trimethoprim sulfamethoxazole in patients with acquired immune deficiency syndrome and Pneumocystis carinii pneumonia. Ann Allergy 1989;62:177-9.
84. Makadon HJ, Silin JG. Prevention of HIV infection in primary care: current practices, future possibilities. Ann Intern Med 1995;123:715-9.
85. Gabel LL, Crane R, Ostrow DC. HTV-related disease: family physicians' multiple opportunities for preventive intervention. J Am Board Fam Pract 1994:7:218-24.
86. Centers for Disease Control and Prevention. Recommendations of the US Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR 1994;43(RR-11):1-20.
87. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N EnglJ Med 1994; 331:1173-80.
88. Centers for Disease Control and Prevention. Casecontrol study of HIV seroconversion in health-care workers after percutaneous exposure to HTV-infected blood-France, United Kingdom, and United States, January 1988-August 1994. MMWR 1995;44:929-33.